CIK 0000748592 · Non-accelerated filer<br>Smaller reporting company
Ernexa Therapeutics Inc.
Sign in to watch- Ticker
- ERNA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 311103425
- Phone
- (617) 798-6700
- Business address
- 1035 CAMBRIDGE STREET, SUITE 18A, CAMBRIDGE, MA, 02141
- Former names
- Eterna Therapeutics Inc., Brooklyn ImmunoTherapeutics, Inc., NTN BUZZTIME INC, NTN COMMUNICATIONS INC
Securities
- ERNA Common Stock Nasdaq
- ERNAW Warrants Nasdaq
- DEFA14A Proxy Proxy Materials
- 8-K Event Delisting notice · Other events
- 8-K Event Executive or director change
- 4 Grant or award CFO and EVP acquired 15,000 shares (grant or award)
- 4 Grant or award CEO acquired 25,000 shares (grant or award)
- 4 Grant or award VP of Finance acquired 3,000 shares (grant or award)
- 4 Open-market sale 10% owner sold 36,679 shares at an average $6.41 ($235,134)
- 8-K Event Material agreement · New debt or obligation
- 10-K Report Annual Report
- 8-K Event Results of operations
- 8-K Event Other events
- SC 13G/A Stake Amended Statement of Ownership
- SC 13D Stake Beneficial Ownership Report
- SC 13D Stake Beneficial Ownership Report
- SC 13G/A Stake Amended Statement of Ownership
- 4 Open-market buy Director bought 5,652 shares at an average $4.00 ($22,598)
- 4 Open-market buy Director bought 5,000 shares at an average $3.96 ($19,792)
- 8-K Event Other events
- 4 Open-market sale 10% owner sold 22,835 shares at an average $5.11 ($116,574)
- 8-K Event Material agreement · Agreement ended · New debt or obligation
Page 33 of 77 · 1,525 filings